Retatrutide

Researchers searching for Retatrutide for sale will find this listing offers the most studied triple-agonist research peptide available in a sealed 30mg vial at 99+% purity. Buy Retatrutide here with confidence: every order ships same-day from a US warehouse through a vetted research supplier with HPLC-verified identity and an independent certificate of analysis. The Retatrutide price on this page represents the current discounted rate with no hidden fees at checkout.

Retatrutide — also known by its Eli Lilly research designation LY3437943 — is a long-acting synthetic peptide that simultaneously activates three receptors central to metabolic regulation: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-receptor engagement distinguishes Retatrutide from earlier single- or dual-agonist incretin compounds and has made the 30mg Retatrutide vial one of the most requested tools in contemporary GLP-1 receptor pharmacology research. The compound is available for research purchase as a lyophilized powder, and the Retatrutide 30mg format provides enough material for extended in-vitro study programs.

Mechanism of Action

Retatrutide engages three pharmacologically distinct receptor systems within a single molecular scaffold, a feature that sets it apart from earlier incretin research compounds. At the GLP-1 receptor, Retatrutide acts as an agonist in a manner consistent with other GLP-1R peptide agonists studied in the incretin literature: receptor activation stimulates adenylyl cyclase through a Gs-coupled pathway, elevates intracellular cyclic AMP in target tissues, and modulates insulin secretion in a glucose-dependent manner in pancreatic beta-cell research models. GLP-1 receptor engagement also influences gastric emptying kinetics and central satiety signaling via vagal afferents and hypothalamic circuits.

At the GIPR, Retatrutide adds a second layer of incretin axis engagement. GIP receptor activation in adipose tissue and islet beta cells has been studied in metabolic research models, and the combination of GLP-1R and GIPR co-activation is a pharmacological strategy that first emerged in the clinical program for tirzepatide. Retatrutide extends this dual-agonist architecture by adding a third receptor arm.

The glucagon receptor element is the most mechanistically novel component of the Retatrutide triple-agonist profile. GCGR agonism in isolation promotes hepatic glycogenolysis and energy expenditure through thermogenic signaling, effects that are counterbalanced in a combined-agonist context by GLP-1R and GIPR co-activation. Preclinical pharmacology literature investigating triple-agonist scaffolds suggests that balanced GCGR engagement in the context of GLP-1R and GIPR activity results in a distinct metabolic research phenotype not achievable with single or dual receptor targeting.

The molecular architecture of Retatrutide incorporates a fatty acid conjugation enabling extended pharmacokinetic behavior in research models, which accounts for the long-acting profile noted in the Eli Lilly clinical investigation program. This structural feature is common to commercially developed GLP-1R agonists and allows the peptide to be studied at lower molar concentrations over extended in-vitro incubation windows. The combination of GLP-1R, GIPR, and GCGR activity in one peptide scaffold provides researchers with a pharmacological tool that cannot be replicated by combining individual receptor-selective agonists.

Chemical Profile

Retatrutide (LY3437943) is a synthetic peptide agonist incorporating a conjugated fatty acid side chain to extend circulatory half-life in pharmacokinetic research models. Its molecular architecture is derived from the GIP peptide backbone with selective amino acid substitutions that confer simultaneous agonist activity at GLP-1R and GCGR in addition to GIPR. The specific amino acid sequence is proprietary to Eli Lilly and has not been fully published in the open literature; the research-grade material supplied in this 30mg vial is synthesized to match the reported pharmacological profile.

The peptide is supplied as a lyophilized (freeze-dried) white to off-white powder in a sealed glass vial under inert atmosphere. Lyophilization removes water while preserving molecular integrity and extends ambient shelf life relative to liquid formulations. The vial contains 30mg of Retatrutide at 99+% purity as verified by HPLC. Molecular weight has not been officially published by the originator; vendor-supplied specifications describe a high-molecular-weight acylated peptide consistent with published GLP-1R agonist analogues in this class. The compound requires reconstitution with bacteriostatic water or sterile saline prior to use in research assays.

Research Applications

Retatrutide has become a significant compound of interest in GLP-1 receptor pharmacology research following Phase 1 and Phase 2 clinical investigations conducted by Eli Lilly. The published clinical data, particularly from the Phase 2 NEJM study of 2023, generated substantial interest in the triple-agonist mechanism across preclinical and translational research communities.

In GLP-1 receptor biology research, Retatrutide is investigated as a pharmacological probe for understanding simultaneous multi-receptor incretin engagement. Cell-based assay systems using HEK293 cells expressing GLP-1R, GIPR, and GCGR individually or in combination are used to characterize receptor binding affinity, cAMP signaling amplitude, and receptor internalization dynamics. These assays allow researchers to dissect the contribution of each receptor arm to the combined pharmacological profile.

In metabolic signaling research, Retatrutide is studied in rodent models of diet-induced obesity and related metabolic phenotypes. Published preclinical pharmacology literature on triple-receptor GLP-1/GIP/glucagon agonism has used compounds in this class to investigate adipose tissue remodeling, hepatic lipid accumulation, and mitochondrial activity in brown adipose tissue. The GCGR component has attracted particular interest for its contribution to thermogenic signaling, distinguishing triple-agonist pharmacology from GLP-1/GIP dual agonism.

In pancreatic islet biology, the glucose-dependent insulin secretion pathway engaged by GLP-1R and GIPR co-activation is studied using isolated islet preparations and MIN6 beta-cell models. Retatrutide provides researchers with a single-compound tool for simultaneously probing both incretin receptors in these systems without the confounding variables introduced by combining two separate agonist compounds at independently calibrated doses.

The compound is also used in hypothalamic neuropeptide circuit research, where GLP-1 receptor populations on arcuate nucleus and brainstem neurons regulate satiety signaling. Triple-agonist probes such as Retatrutide allow investigators to study how simultaneous peripheral and central receptor engagement modulates neuropeptide Y, agouti-related peptide, and pro-opiomelanocortin neuron activity in preclinical models.

All research applications described here refer to published preclinical and clinical literature contexts. Retatrutide is an investigational compound, is not FDA-approved for any indication, and is not intended for human or veterinary use, diagnosis, or treatment.

Reconstitution & Dosing Reference

The following reconstitution guidance is provided as a research reference for in-vitro laboratory use only and does not constitute human dosing instruction or medical guidance. Researchers working with Retatrutide 30mg vials should consult peer-reviewed literature and institutional SOPs for protocol-specific requirements.

To reconstitute Retatrutide, inject bacteriostatic water (BW) or sterile saline along the vial wall using a 1 mL insulin syringe or reconstitution needle. Avoid direct injection onto the lyophilized cake to prevent foaming and peptide degradation. Do not shake; invert or gently roll the vial until the powder is fully dissolved. The resulting solution should be clear to slightly opalescent with no visible particulates.

For a standard 30mg vial, adding 3 mL of bacteriostatic water yields a 10 mg/mL stock concentration. Adding 6 mL yields a 5 mg/mL stock. For microdose research assay work, adding 30 mL yields a 1 mg/mL stock. Researchers preparing cell-based assay dilutions typically prepare serial dilutions from the reconstituted stock in phosphate-buffered saline or culture medium to reach nanomolar working concentrations appropriate for receptor activation studies.

In published Eli Lilly Phase 2 clinical research, the human investigation program used once-weekly subcutaneous injection formats; however, this information is cited here strictly as published literature context. All dosing decisions for in-vitro or animal research programs should be derived from peer-reviewed preclinical literature and be approved through appropriate institutional oversight.

Store reconstituted Retatrutide at 2-8 degrees Celsius. Use within 30 days of reconstitution. Do not freeze reconstituted solution.

Storage & Handling

Lyophilized Retatrutide powder should be stored at -20 degrees Celsius upon receipt for long-term stability. When stored correctly in the sealed vial, lyophilized Retatrutide retains stability for 24 months or more. Short ambient-temperature transit during shipping does not meaningfully degrade the lyophilized powder. Transfer to freezer storage immediately upon receipt.

Protect the vial from direct light. UV exposure can degrade acylated peptide side chains over time. Store in an opaque container or the original secondary packaging if available.

After reconstitution, store the solution at 2-8 degrees Celsius (refrigerator temperature, not frozen). Reconstituted Retatrutide is stable for up to 30 days under these conditions. Avoid multiple freeze-thaw cycles of the reconstituted solution. For research programs requiring longer-term storage of reconstituted material, aliquoting into single-use volumes before freezing at -20 degrees Celsius is standard laboratory practice.

Where to Buy Retatrutide

Researchers looking for where to buy Retatrutide online should prioritize vendors that provide batch-specific HPLC documentation, independent mass-spectrometry identity confirmation, and domestic US fulfillment. Retatrutide is a high-molecular-weight acylated peptide with a specific triple-agonist receptor profile that requires verified synthesis to function correctly as a research tool. Purchasing from a vendor that cannot provide a certificate of analysis introduces unacceptable variability into receptor binding and signaling research programs.

PeptideDeck lists Retatrutide for sale from a vetted US research supplier meeting all of these criteria. The Retatrutide price on this page reflects 99+% HPLC-verified purity, third-party QC documentation, and same-day shipping from a US warehouse. This listing provides the 30mg vial format, which is the standard research quantity for extended GLP-1 receptor pharmacology programs.

When evaluating Retatrutide for sale listings, researchers should confirm: (1) the vendor publishes lot-level COA data including HPLC chromatogram and mass-spec results; (2) product ships from domestic US inventory to avoid customs delays; (3) the listing specifies the correct research-grade lyophilized format. This listing satisfies all three criteria. Click through to our partner to confirm live stock availability and complete checkout with encrypted secure payment.

Quality Assurance & COA

Each Retatrutide 30mg vial supplied through this listing is produced under cGMP-aligned synthesis conditions and verified by high-performance liquid chromatography (HPLC) and mass spectrometry prior to release. HPLC analysis confirms purity at 99+% and identifies any detectable impurity peaks above the reporting threshold. Mass spectrometry confirms molecular identity against the expected molecular weight of the Retatrutide compound, ensuring that the material in the vial corresponds to the labeled peptide.

Independent third-party laboratory verification adds an additional layer of quality assurance beyond internal vendor testing. The batch-specific certificate of analysis is available on request from our partner vendor; researchers should request the COA for their specific lot number at the time of purchase. All testing is conducted prior to shipping, and only lots that pass purity and identity thresholds are released for sale.